OCTA and Polypoidal Choroidal Vasculopathy

Sponsor
Federico II University
Study ID
NCT04714242
Status
Completed

Conditions

  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
60 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.

Key Dates

First listed
Jan 19, 2021
Start date
Jan 15, 2019
Status verified
Jan 2021
Primary completion
Dec 15, 2020
Completion
Dec 20, 2020

Study Design

Enrollment
60 participants (actual)

Arms

  • Arm: Patients underwent anti-VEGF therapy
    intravitreal Anti-VEGF therapy: Three monthly intravitreal injections
  • Arm: Control Group
    Healthy eyes without actual and previous ocular diseases

Primary Outcome Measure

Study of vascular features of choroid in polypoidal choroidal vasculopathy after intravitreal injections of Ranibizumab [ Time Frame: 12 Months ]

Related Studies